MEDICAL DEVICES FOR DIABETES MANAGEMENT: A COMPREHENSIVE REVIEW OF CURRENT TECHNOLOGIES AND EMERGING TRENDS
DOI:
https://doi.org/10.22159/ijpps.2026v18i8.59940Keywords:
Keywords Software as medical device (SAMD), Self-monitoring blood glucose (SMBG), Continuous glucose monitoring (CGM), Diabetes management care.Abstract
Objective: This article reviews the advancements in medical device technologies for diabetes management, focusing on devices such as self-monitoring blood glucose meters, continuous glucose monitoring systems, smart insulin pens, Automated insulin delivery systems and new non- invasive and wearable biosensing technologies
Methods: We conducted a narrative review of the published literature and recent technological advances in devices for diabetes monitoring and management. The review discussed traditional glucose monitoring systems, wearable and non-invasive biosensors, microneedle-based devices, smart textile wearables, self-powered biosensors and diabetes technologies integrated with digital health.
Results: The management of diabetes has been changing greatly due to the fast development of medical device technologies designed to enhance the quality of glucose monitoring and therapeutic results. The given review will be a summary of the known devices used in diabetes management Self-monitoring Blood Glucose (SMBG) meters, Continuous Glucose Monitoring (CGM) systems, Smart insulin pens, and Automated Insulin Delivery (AID) platforms that help to improve glycaemic control and patient quality of life. The other innovations mentioned in the article include non-invasive glucose monitoring, microneedle-based, multi-analyte biosensing systems as well as self-powered biosensors to monitor continuous metabolism, smart textile wearables, and microneedle-based biosensors. Combining state-of-the-art sensors with digital health and smart decision-support systems is facilitating the provision of more personalized diabetes management. The technologies are directions to next-generation diabetes management despite the current challenges in terms of technologies and regulations.
Conclusion: Rapid advances in diabetes related medical devices are revolutionizing management of diabetes by improving efficiency of monitoring, accuracy of therapy and patient centred care. Promising ways for next generation personalized diabetes management include emerging wearable and non-invasive technologies but technical, clinical and regulatory challenges still exist.
Downloads
References
1. IDF Diabetes Atlas. 11th ed. Brussels: International Diabetes Federation; 2025.
2. Sun MT, Hine J, Taraporewalla K, McGowan R, Liew D. Pros and cons of continuous glucose monitoring in the hospital setting and beyond. World J Diabetes. 2021;12(10):1597-1611.
3. Wu X, Zhao X, Chen W, Chen Q, Kong L, Li P. A systematic review of continuous glucose monitoring sensors: principles, core technologies and performance evaluation. Sens Actuators Rep. 2025;10:100361.
4. Moses JC, Chokkalingam R, Soundarapandian K. Non-invasive blood glucose monitoring technology: challenges and perspectives. mHealth. 2024;10:34.
5. Conway RB, Snell-Bergeon J, Honda-Kohmo K, Lee A, Tanaka N, Mbwambo S, et al. Disparities in diabetes technology uptake in youth and young adults with type 1 diabetes: a global perspective. J Endocr Soc. 2024;9(1):bvae210.
6. Heller A, Feldman B. Electrochemical glucose sensors and their applications. Chem Rev. 2008;108(7):2482-2505.
7. Clark LC Jr, Lyons C. Electrode systems for continuous monitoring in cardiovascular surgery. Ann N Y Acad Sci. 1962;102(1):29-45.
8. Wilson R, Turner APF. Glucose oxidase: an ideal enzyme. Biosens Bioelectron. 1992;7(3):165-185.
9. Newman JD, Turner APF. Home blood glucose biosensors: a commercial perspective. Biosens Bioelectron. 2005;20(12):2435-2453.
10. Tsujimura S, Kojima S, Kano K. Engineered glucose dehydrogenases and their applications. Biotechnol Lett. 2014;36:1735-1742.
11. Matsushita K, Toyama H, Adachi O. Respiratory chains and bioenergetics of acetic acid bacteria. Adv Microb Physiol. 1994;36:247-301.
12. Verduyn C. Physiology of yeasts in relation to alcoholic fermentation. Antonie Van Leeuwenhoek. 1991;60:325-353.
13. Tang Z, Du X, Louie RF, Kost GJ. Effects of maltose interference on GDH-PQQ based glucose meters. Diabetes Technol Ther. 2000;2(4):501-511.
14. Kost GJ, Tran NK, Abad V, Louie RF. False glucose readings with GDH-PQQ meters. Clin Chem. 2008;54(5):855-857.
15. Sode K, Ohta T, Ohara T, Sugiura Y. Development of FAD-dependent glucose dehydrogenase for biosensing. Biosens Bioelectron. 2008;23(7):959-965.
16. Ferri S, Kojima K, Sode K. Review of FAD-GDH glucose sensors. J Diabetes Sci Technol. 2011;5(5):1068-1076.
17. Kaplan LA, Pesce AJ. Clinical Chemistry: Theory, Analysis, Correlation. 3rd ed. St. Louis: Mosby; 1996.
18. Burtis CA, Ashwood ER, Bruns DE. Tietz Textbook of Clinical Chemistry and Molecular Diagnostics. 4th ed. St. Louis: Elsevier; 2006.
19. Sacks DB. Carbohydrates. In: Burtis CA, Ashwood ER, Bruns DE, editors. Tietz Fundamentals of Clinical Chemistry. 6th ed. Philadelphia: Elsevier; 2008. p. 367-400.
20. Kricka LJ. Principles of chemical measurement in laboratory medicine. Clin Chem. 1998;44(8):1683-1690.
21. Luo Y, Doonan S, Liu H. Limitations of hexokinase-based glucose assays in POC devices. Clin Biochem. 2009;42(12):1237-1243.
22. Hwang S, Cha K, Lee SM. Comparison of glucose dehydrogenase-based biosensors. Anal Chim Acta. 2014;831:1-15.
23. Nichols JH. Laboratory and POCT glucose testing: strengths and limitations. Clin Lab Med. 2015;35(2):203-216.
24. Clarke SF, Foster JR. A history of blood glucose meters and their role in self-monitoring of diabetes mellitus. Br J Biomed Sci. 2012;69(2):83-93.
25. Malanda UL, Welschen LM, Riphagen II, Dekker JM, Nijpels G, Bot SD. Self-monitoring of blood glucose in patients with type 2 diabetes mellitus not using insulin. Cochrane Database Syst Rev. 2012;(1):CD005060.
26. U.S. Food and Drug Administration. Software as a medical device (SaMD): clinical evaluation. Silver Spring (MD): FDA; 2017.
27. Boughton CK, Hovorka R. Automated insulin delivery systems: state of the art. Lancet Diabetes Endocrinol. 2019;7(9):647-656.
28. Breton MD, Kovatchev BP. Hybrid closed-loop systems for type 1 diabetes. Endocrinol Metab Clin North Am. 2020;49(1):95-108.
29. Forlenza GP, Ekhlaspour L, Ferrara C, Argento NB, Laffel LM. Modern insulin pumps and automated insulin delivery systems. Diabetes Technol Ther. 2022;24(6):389-402.
30. U.S. Food and Drug Administration. Premarket approvals and clearances for Medtronic, Tandem, and Insulet AID systems. Silver Spring (MD): FDA; 2023-2024.
31. Battelino T, Danne T, Bergenstal RM, Amiel SA, Beck R, Biester T, et al. Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range. Lancet Diabetes Endocrinol. 2019;7(10):845-854. doi:10.1016/S2213-8587(19)30090-6.
32. Basu A, Slama MQ, Nicholson WT, Donner T. Continuous glucose monitoring: technology and clinical use. Endocr Rev. 2023;44(2):261-289.
33. Beck RW, Riddlesworth T, Ruedy K, Ahmann A, Bergenstal R, Haller S, et al. Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections: the DIAMOND randomized clinical trial. JAMA. 2017;317(4):371-378. doi:10.1001/jama.2016.19975.
34. Downie E, Craig ME. Real-time continuous glucose monitoring in diabetes. Pediatr Clin North Am. 2020;67(4):701-712.
35. Aleppo G, Ruedy KJ, Bailey TS. Safety and performance of real-time continuous glucose monitoring. Diabetes Technol Ther. 2017;19(6):334-342.
36. Battelino T, Danne T, Bergenstal RM, et al. Clinical benefits of flash glucose monitoring. Diabetes Care. 2019;42(8):1471-1478.
37. Zaccardi F, Webb DR, Yates T, Davies MJ. Self-monitoring and intermittently scanned CGM: accuracy and limitations. Diabetes Obes Metab. 2020;22(5):709-717.
38. Bruen D, Delaney C, Florea L, Diamond D. Glucose sensing for diabetes monitoring: recent developments. Sensors (Basel). 2017;17(8):1866.
39. Pandey R, Paidi SK, Valdez TA, Zhang C, Spegazzini N, Dasari RR. Noninvasive Raman spectroscopy for glucose monitoring. Anal Chem. 2017;89(1):391-410.
40. Scholtes-Timmerman MJ, Bijlsma S, Fokkert MJ, Slingerland R, van Veen SJ. Raman spectroscopy as a promising tool for noninvasive point-of-care glucose monitoring. J Diabetes Sci Technol. 2014;8(5):974-979. doi:10.1177/1932296814543104.
41. Bandodkar AJ, Jia W, Wang J. Tattoo-based wearable electrochemical devices: a review. Electroanalysis. 2015;27(3):562-572. doi:10.1002/elan.201400574.
42. Gao W, Emaminejad S, Nyein HYY, Challa S, Chen K, Peck A, et al. Fully integrated wearable sensor arrays for multiplexed in situ perspiration analysis. Nature. 2016;529(7587):509-514. doi:10.1038/nature16521.
43. Iliopoulos K, Furse CM. Microwave and millimeter-wave non-invasive glucose sensing. Sensors (Basel). 2022;22(3):1232.
44. Habib MA, AlShareef M, Ibhrahim M, Shamim A. RF-based wearable glucose sensors: opportunities and challenges. IEEE Access. 2023;11:34580-34592.
45. Pleitez MA, Glück M, Von Lilienfeld-Toal H. Direct optical glucose sensing in biological tissues by mid-infrared spectroscopy. Sci Rep. 2015;5:12817.
46. Bogé M, Brage H, Jansson P. Non-invasive glucose sensing using near-infrared spectroscopy: current status. J Diabetes Sci Technol. 2020;14(1):44-52.
47. Caduff A, Hirt E, Feldman Y, Ali Z, Heinemann L. First experiences with a non-invasive multisensor system for continuous glucose monitoring. Diabetes Technol Ther. 2003;5(4):591-598.
48. Pal K, Roy S, Sarkar N, Ghosh D. Wearable biosensors for non-invasive physiological monitoring. Biosensors (Basel). 2022;12(6):386.
49. Heikenfeld J, Jajack A, Rogers J, Gutruf P, Tian L, Pan T, et al. Wearable sensors: modalities, challenges, and prospects. Lab Chip. 2018;18(2):217-248. doi:10.1039/C7LC00914C.
50. Stoppa M, Chiolerio A. Wearable electronics and smart textiles: a critical review. Sensors (Basel). 2014;14(7):11957-11992. doi:10.3390/s140711957.
51. Gowda R, Dagdeviren C. Flexible and skin-integrated electronics for glucose monitoring. Adv Healthc Mater. 2021;10(1):2001194.
52. Klonoff DC, Kerr D. Smart pens: improving diabetes management through connected insulin delivery devices. J Diabetes Sci Technol. 2022;16(3):613-621. doi:10.1177/19322968211070823.
53. Sempionatto JR, Lin M, Yin L, et al. An epidermal patch for sweat glucose monitoring. Sci Adv. 2021;7(16):eabd0139.
54. Ronkainen NJ, Halsall HB, Heineman WR. Electrochemical biosensors. Chem Soc Rev. 2010;39(5):1747-1763.
55. Zhang Y, Bai W, Ma M, et al. Nanomaterial-based electrochemical sensors for glucose detection. Anal Chim Acta. 2020;1120:1-19.
56. Al-Ghaithi K, Al-Ruqeishi M, Al-Hinai M, Dobretsov S, Al-Hinai A. Emerging nanomaterial-based non-invasive glucose sensors: challenges and prospects. Sensors (Basel). 2023;23(5):2441.
57. Wang J, Windmiller JR. Self-powered biosensors for health monitoring. Biosens Bioelectron. 2013;39(1):1-11. doi:10.1016/j.bios.2012.05.048.
58. Bandodkar AJ, Wang J. Non-invasive wearable electrochemical sensors: a review. TrAC Trends Anal Chem. 2014;76:173-185. doi:10.1016/j.trac.2015.09.012.
59. Peters AL, Ahmann AJ, Battelino T, Evert A, Hirsch IB, Murad MH, et al. Diabetes technology: continuous subcutaneous insulin infusion, continuous glucose monitoring, and automated insulin delivery systems. J Clin Endocrinol Metab. 2023;108(4):e239-e289.
60. Rickels MR, Robertson RP, Markmann JF, Hayek A, Khoo C, Maffi P, et al. Improving outcomes of islet transplantation and stem cell-derived therapies for diabetes: an international consensus statement. Nat Rev Endocrinol. 2023;19(7):415-432.
61. . ISO 15197:2013. In vitro diagnostic test systems—Requirements for blood-glucose monitoring systems for self-testing in managing diabetes mellitus. Geneva: ISO; 2013.
62. . Clinical evaluation of medical devices: IMDRF/GRRP WG/N56FINAL:2020. IMDRF; 2020.
63. Shapiro AMJ, Pokrywczynska M, Ricordi C. Stem cell therapies for diabetes: progress, challenges and future directions. Nat Rev Endocrinol. 2024;20(3):165-182.
64. Yoo JH, Kim JH. Advances in continuous glucose monitoring and integrated devices for management of diabetes with insulin-based therapy. Diabetes Metab J. 2023;47:27-41.
65. Food and Drug Administration. Overview of device regulation. Silver Spring (MD): FDA Center for Devices and Radiological Health; 2025.
Published
How to Cite
Issue
Section
Copyright (c) 2026 Vivek Reddy Murthannagari, DIVYA BASKARAN, AMIT KUMAR DUBEY, KESARI NANDAN DWIVEDI
This work is licensed under a Creative Commons Attribution 4.0 International License.